Today has seen the launch of Experimental &
Translational Stroke Medicine, a journal dedicated to the gathering and
dissemination of new knowledge in the field of experimental stroke research, with the
aim of improving the quality of stroke research and facilitating the successful
translation of novel treatment strategies into clinical practice.

Amongst the first articles to be published in the
journal are detailed reviews on potential new drug candidates
currently nearing the end of development such as the hematopoietic factors
G-CSF (Minnerup et al), and EPO (Byts and Siren). A detailed review is given by Dr
Linker and Dr Lee on recent MS models which
are more clinically relevant than the established experimental autoimmune
encephalitis. In addition, Dr Gee and colleagues provide clear-cut evidence regarding the
possible detrimental effects of the mucosal
administration of antigen in terms of autoimmunity.

With their primary aim being to improve the quality of
research in this field and reduce translational failure from bench to beside,
Editor-in-Chief Wolf-Rüdiger Schäbitz and Deputy Editor Christoph Kleinschnitz
explain in their launch editorial how they
believe that the open access format BMC offers "is ideally suited to rapidly and broadly disseminating novel findings and promoting fruitful discussion amongst active stroke researchers" and how they would like to “encourage
the stroke community to make full use of this very welcome resource”.

For further information about the journal, please visit
the journal’s website or view the instructions for
authors if you would like to submit a manuscript.